Skip to main content
Terug
Watch Compare

Protagenic Therapeutics, Inc.\new

Datakwaliteit: 100%
Ook genoteerd als PTIXW OTC
PTIX
OTC Manufacturing Chemicals
€ 0,59
▼ € 0,11 (-15,22%)
Marktkapitalisatie: 1,34 M
Prijs
€ 0,69
Marktkapitalisatie
1,34 M
Dagbereik
—
52-Weeksbereik
—
Volume
—
Openen —
50D / 200D Gem.
—
50D / 200D Gem.
—

Quick Summary

Belangrijkste Punten

Negative free cash flow of -3,30 M

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
N/A
ROICN/A
Net MarginN/A
Op. MarginN/A

Veiligheid

Debt / Equity
N/A
Current Ratio0,34
Interest Coverage-28,83

Waardering

PE (TTM)
-0,27
Boven sectorgemiddelde (-1,49)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1385 peers)
Metriek Aandeel Sector Mediaan
P/E -0,3 -1,5
P/B — 1,6
ROE % — -54,0
Net Margin % — -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3

Koersdoel Analisten

Geen analistendekking beschikbaar

Winstschattingen

Geen toekomstige schattingen beschikbaar

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 0,0 Net Income (TTM) -4,99 M
ROE N/A ROA -105,70%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -3,30 M
ROIC N/A FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 0,34
Interest Coverage -28,83 Asset Turnover 0,00
Working Capital -4,52 M Tangible Book Value -4,49 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0,27 Forward P/E N/A
P/B Ratio N/A P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -247,25%
Market Cap 1,34 M Enterprise Value 1,34 M
Per Share
EPS (Diluted TTM) -4,10 Revenue / Share 0,00
FCF / Share -1,71 OCF / Share -1,71
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 66,21%
SBC-Adj. FCF -3,86 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Revenue 0,0 0,0 0,0 0,0 —
Net Income -5,53 M -5,00 M -3,56 M -4,52 M -2,55 M
EPS (Diluted) -1,13 -1,15 — — —
Gross Profit — — — — —
Operating Income -5,70 M -4,53 M -3,56 M -4,14 M -2,55 M
EBITDA — — — — —
R&D Expenses 3,84 M 3,32 M 1,59 M 1,14 M 699.797,0
SG&A Expenses — — — — —
D&A — — — — —
Interest Expense 107.682,0 107.682,0 137.456,0 496.912,0 —
Income Tax — — — — —

Balance Sheet

Annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Total Assets 1,96 M 4,32 M 8,04 M 11,06 M 879.247,0
Total Liabilities 942.759,0 655.252,0 1,12 M 1,12 M 2,03 M
Shareholders' Equity 1,01 M 3,67 M 6,92 M 9,94 M -1,15 M
Total Debt — — — — —
Cash & Equivalents — — — — 671.091,0
Current Assets 1,88 M 4,20 M 8,04 M 11,06 M 879.247,0
Current Liabilities 942.759,0 655.252,0 1,12 M 799.535,0 655.187,0